Article
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.
Cancer discovery - 1 Jun 2021
Lo Yuan-Hung, Kolahi Kevin S, Du Yuhong, Chang Chiung-Ying, Krokhotin Andrey, Nair Ajay, Sobba Walter D, Karlsson Kasper, Jones Sunny J, Longacre Teri A, Mah Amanda T, Tercan Bahar, Sockell Alexandra, Xu Hang, Seoane Jose A, Chen Jin, Shmulevich Ilya, Weissman Jonathan S, Curtis Christina, Califano Andrea, Fu Haian, Crabtree Gerald R, Kuo Calvin J
Abstract excerpt
Mutations in ARID1A rank among the most common molecular aberrations in human cancer. However, oncogenic consequences of ARID1A mutation in human cells remain poorly defined due to lack of forward genetic models. Here, CRISPR/Cas9-mediated ARID1A knockout (KO) in primary TP53-/- human gastric organoids induced morphologic dysplasia, tumorigenicity, and mucinous differentiation. Genetic WNT/β-catenin activation...
Topics
Join the communities discussing this publication.